Document is current
Any future updates will be listed below
-
Authors
Larsen, Malin https://orcid.org/0009-0004-6820-0583
Mendelsohn, Daniel H. https://orcid.org/0000-0001-9172-6031
Kleefeld, Felix https://orcid.org/0000-0002-0643-7313
Meinke, Peter https://orcid.org/0000-0003-3359-3837
Schoser, Benedikt https://orcid.org/0000-0002-2757-8131
-
Funding
Funding for this research was provided by:
HORIZON EUROPE Marie Sklodowska-Curie Actions (Project 101169266)
HORIZON EUROPE Marie Sklodowska-Curie Actions (HORIZON-MSCA-2023-DN-01)
Klinikum der Universität München
- License Information
-
More Information
Article History
Received: 1 April 2026
Revised: 29 April 2026
Accepted: 9 May 2026
First Online: 14 June 2026
Declarations
:
: B.S. has received research grants from the EU Horizon 2022 programs ComPaSS, PaLaDIn, and ENTRY-DM, PepGen DM research; received consulting fees from Alexion, Amicus, Astellas, Avidity, Denali, Dyne, Sanofi, and Johnson & Johnson; honoraria from Alexion, Argenx, Astellas, Dyne, Kedrion, and Sanofi; support for attending meetings and/or travel from Astellas, Amicus, and Sanofi; has participated in advisory boards for Amicus, Astellas, Avidity, Dyne, and Encoded; and declares no stocks or shares. B.S. and F.K. received a Mytonia Dystrophy Foundation pilot grant for DM2 Biomarker exploration. M.L., D.H.M., and P.M. declare that they have no conflict of interest.
: The manuscript does not contain clinical studies or patient data.
